OBJECTIVES: Opioid overdose and misuse of prescription opioids remain a clinical and economic burden. However, access to available medication assisted treatment (MAT) employing buprenorphine remains challenging. Literature suggests that many waivered clinicians do not provide buprenorphine treatment. Also, the accuracy of the publicly available treatment locator is unknown. Therefore, the objective of this study was to determine the availability of buprenorphine provision by waivered clinicians in Texas. METHODS: The list of Texas-waivered clinicians was downloaded from the Substance Abuse and Mental Health Services Administration (SAMHSA) website in May 2019 to address the study objective. After deleting duplicates, the list was matched by provider name and address to publicly available lists from Texas healthcare licensing boards (e.g., Texas Medical Board) to obtain demographic information. To determine the provision of buprenorphine, investigators made calls to providers’ offices during regular business hours from October to December 2019. Investigators used a standardized script, simulating a patient in need of treatment to investigate the availability of buprenorphine treatment and other OUD pharmacotherapy. Descriptive statistics and inferential analysis (Chi-square) were used to evaluate study variables. RESULTS: After deleting duplicates, the resulting list of 1,279 waivered clinicians as listed by SAMHSA, were contacted. The total number of clinician offices that responded was 589, of which 342 (58.1%) provided buprenorphine. Comparatively, only 9.1% of clinicians provided methadone. Inferential statistical results found no significant differences with regards to race, gender and age. CONCLUSIONS: Considering that less than 60% of waivered clinicians listed on the treatment locater provide buprenorphine, an accurate, publicly available list of waivered-clinicians is needed. Many waivered-clinicians are not actively engaged in treating OUD. Perhaps, incentive programs would encourage clinicians to engage the urgent need for OUD treatment. More research is needed to assess OUD treatment and the economic and clinical outcomes of more widespread MAT treatment availability.